93 completed, 26 unknown, 18 active not recruiting, 18 terminated. 98 Phase 2, 53 Phase 3, 19 Phase 1, 9 Not applicable, 3 Phase 4.
Follow Vinblastine: new trials by email Literature Review of Vinblastine trials Research Report on Vinblastine
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase II Study Of Nivolumab Plus AVD In Pediatric, Adolescent, And Young Adult Patients With CHL Nivolumab, Doxorubicin Hydrochloride, Vinblastine - Hodgkin Lymphoma | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 15 | 2026-08-19 | 2026-08-31 |
| Phase 1/2 Study of Mirdametinib + Vinblastine for Newly Diagnosed/Previously Untreated PLGG + Activation of MAPK Mirdametinib - Pediatric Low-grade Glioma | Phase 1 / Phase 2 | Recruiting | St. Justine's Hospital | 50 | 2026-01-12 | 2026-10-16 |
| Chemoimmunotherapy for ALK+ Relapsed/Refractory ALCL Vinblastine (Velban), Brentuximab vedotin (Adcetris), Nivolumab (Opdivo) - Anaplastic Large Cell Lymphoma, ALK-Positive | Phase 2 | Recruiting | New York Medical College | 20 | 2025-08-07 | 2026-05-20 |
| Perioperative Durvalumab With Neoadjuvant ddMVAC in Patients With Muscle-Invasive Bladder Cancer (NIAGARA-2) Durvalumab, Methotrexate, Vinblastine - Urinary Bladder Neoplasms, Immune Checkpoint Inhibitors | Phase 2 | Recruiting | AstraZeneca | 150 | 2025-05-15 | 2026-10-08 |
| Nivo40-AVD for Advanced Classic Hodgkin Lymphoma Nivolumab, Doxorubicin, Vinblastine - Hodgkin Lymphoma, Adult | Phase 2 | Recruiting | National Medical Research Radiological Centre of the Ministry of Health of Russia | 54 | 2025-04-15 | 2025-11-26 |
| Personalized Reduction of Chemotherapy Intensity Through ctDNA Evaluation for the Treatment of Patients With Advanced Hodgkin Lymphoma Biospecimen Collection, Computed Tomography, Dacarbazine - Advanced Hodgkin Lymphoma, Classic Hodgkin Lymphoma | Phase 2 | Recruiting | University of Washington | 125 | 2025-03-06 | 2026-09-09 |
| A Study of Brentuximab Vedotin With Doxorubicin, Vinblastine and Dacarbazine in Adults With Hodgkin Lymphoma in India Brentuximab Vedotin, Doxorubicin, Vinblastine - Hodgkin Lymphoma | Phase 4 | Recruiting | Takeda | 124 | 2024-08-28 | 2026-02-23 |
| Drug Screening Using IMD in Bladder Cancer Implantable Micro-Device, Methotrexate, Carboplatin - Muscle Invasive Bladder Urothelial Carcinoma | Early Phase 1 | Enrolling by invitation | Brigham and Women's Hospital | 18 | 2024-06-14 | 2026-05-18 |
| A Study of BV-AVD in People With Bulky Hodgkin Lymphoma Brentuximab vedotin, Doxorubicin, Vinblastine - Hodgkin Lymphoma | Phase 2 | Recruiting | Memorial Sloan Kettering Cancer Center | 71 | 2024-04-17 | 2026-04-23 |
| Pilot Study of Vinblastine and Tovorafenib in Pediatric Patients With Recurrent/Progressive RAF Altered Low Grade Gliomas Tovorafenib, Vinblastine - Low-grade Glioma | Early Phase 1 | Recruiting | Daniel Morgenstern | 57 | 2024-03-21 | 2025-05-15 |
| Pembrolizumab Followed by Chemotherapy for the Treatment of Patients With Classical Hodgkin Lymphoma Biopsy, Biospecimen Collection, Computed Tomography - Classic Hodgkin Lymphoma | Phase 2 | Active not recruiting | Northwestern University | 30 | 2024-02-06 | 2026-07-13 |
| H-9926-LCH III: Treatment Protocol of the Third International Study for Langerhans Cell Histiocytosis Prednisone, Vinblastin, 6-mercaptopuroine, Leucovorin, Methotrexate, Vinblastine, Prednisone - Leukemia | Phase 3 | Withdrawn | University of New Mexico | 2023-08-01 | 2023-08-03 | |
| A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab Biospecimen Collection, Bleomycin Sulfate, Brentuximab Vedotin - Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8 | Phase 3 | Recruiting | National Cancer Institute (NCI) | 1875 | 2023-05-11 | 2026-10-23 |
| Anti-CD30 (Brentuximab Vedotin) With AVD Versus ABVD Chemotherapy Protocol Frontline Therapy in Patients With Advanced Classical Hodgkin Lymphoma Brentuximab Vedotin + Doxorubicin, Vinblastine, and Dacarbazine, Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine - Anti-CD30, Brentuximab | Not applicable | Completed | Helwan University | 60 | 2023-03-01 | 2025-09-15 |
| Fitness-adapted, Pembrolizumab-based Therapy for Untreated Classical Hodgkin Lymphoma Patients 60 Years of Age and Above Pembrolizumab, Doxorubicin, Vinblastine - Classical Hodgkin Lymphoma | Phase 2 | Active not recruiting | University of Virginia | 24 | 2022-07-26 | 2026-05-14 |
| Pediatric Low Grade Glioma - MEKinhibitor TRIal vs Chemotherapy Trametinib, Vinblastine - Grade 1 Glioma, Mixed Glio-neuronal Tumors | Phase 2 | Recruiting | University Hospital, Strasbourg, France | 134 | 2022-05-05 | 2026-08-20 |
| Brentuximab Vedotin in Early Stage Hodgkin Lymphoma Involved site radiotherapy, Doxorubicin, Bleomycin - Hodgkin Lymphoma | Phase 3 | Recruiting | University College, London | 1042 | 2022-04-14 | 2026-07-08 |
| Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer Biopsy Procedure, Biospecimen Collection, Cisplatin - Renal Pelvis and Ureter Urothelial Carcinoma | Phase 2 / Phase 3 | Recruiting | National Cancer Institute (NCI) | 131 | 2021-11-12 | 2026-10-13 |
| A Phase II Multicenter Study of Chemotherapy Versus Chemotherapy Plus Durvalumab (MEDI 4736) in Patients With Lymph Node Positive Urothelial Carcinoma of the Bladder Abiraterone acetate, Durvalumab, Methotrexate - Urothelial Carcinoma, Bladder Cancer | Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 12 | 2021-10-13 | 2026-08-07 |
| Study of Safety and Efficacy of Pembrolizumab and Chemotherapy in Participants With Newly Diagnosed Classical Hodgkin Lymphoma (cHL) (MK-3475-C11/KEYNOTE-C11) Pembrolizumab, Doxorubicin, Vinblastine - Classical Hodgkin Lymphoma | Phase 2 | Completed | Merck Sharp & Dohme LLC | 146 | 2021-10-07 | 2025-06-06 |
Showing 20 of 173. Sign in to see all of them.
Hodgkin Disease (65) · Lymphoma (39) · Urinary Bladder Neoplasms (16) · Carcinoma, Non-Small-Cell Lung (11) · Lung Neoplasms (9) · Melanoma (9) · Lymphoma, Large-Cell, Anaplastic (4) · Prostatic Neoplasms (4) · Recurrence (4) · Urethral Neoplasms (4) · Astrocytoma (3) · Central Nervous System Neoplasms (3) · Glioma (3) · HIV Infections (3) · Leukemia (3)
M.D. Anderson Cancer Center (12) · European Organisation for Research and Treatment of Cancer - EORTC (9) · National Cancer Institute (NCI) (8) · St. Jude Children's Research Hospital (7) · University of Cologne (7) · Memorial Sloan Kettering Cancer Center (6) · SWOG Cancer Research Network (6) · Children's Oncology Group (5) · Stanford University (5) · Children's Cancer and Leukaemia Group (4) · Eastern Cooperative Oncology Group (4) · Gustave Roussy, Cancer Campus, Grand Paris (4) · The Hospital for Sick Children (4) · Alliance for Clinical Trials in Oncology (3) · Northwestern University (3)
United States (101) · Canada (31) · Italy (24) · United Kingdom (24) · France (23) · Germany (17) · Australia (15) · Belgium (15) · Spain (15) · Netherlands (14) · Poland (10) · Austria (8) · Switzerland (8) · Czechia (7) · Denmark (7)
Sandra J. Horning, MD (5) · Anas Younes, MD (3) · Andreas Engert, Prof. (3) · Alessandro M Gianni, MD (2) · Alex F Herrera (2) · Bruce J. Roth, MD (2) · Christophe Ferme (2) · Dieter Koerholz, MD (2) · Eric Bouffet, MD (2) · H. Eghbali, MD (2) · Ian E. Smith, MD (2) · John Martin, MD (2) · Lawrence E. Flaherty, MD (2)
PMID 40135712, PMID 24121121, PMID 37505794, PMID 23509310, PMID 24239220, PMID 27573663, PMID 39620432, PMID 11709567, PMID 12610188, PMID 12972528, PMID 14736927, PMID 15073851, PMID 15837968, PMID 15936157, PMID 16157935, PMID 16258090, PMID 16314615, PMID 16957145, PMID 17097834, PMID 17290057, PMID 17544497, PMID 17602078, PMID 17846017, PMID 17989384, PMID 19001327, PMID 19029421, PMID 19430405, PMID 19786668, PMID 19828373, PMID 19841428, PMID 19933916, PMID 20679620, PMID 20713848, PMID 20818855, PMID 20978195, PMID 21079154, PMID 21224045, PMID 21280197, PMID 21355087, PMID 21444917, PMID 21764821, PMID 21774708, PMID 21895543, PMID 21917759, PMID 22149921, PMID 22156656, PMID 22159586, PMID 22162575, PMID 22371887, PMID 23065953
P30CA016672 (5), U10CA032102 (5), 2023 (3), 2014 (2), P30CA060553 (2), U10CA031946 (2), U10CA180820 (2), U10CA180886 (2), U10CA180888 (2), 2004 (1), 2005 (1), 2009 (1), 2015 (1), 2017 (1), 2018 (1)